Glenview Capital Issues Statement on CVS Health

Rhea-AI Summary

Glenview Capital reports significant progress in CVS Health's (NYSE: CVS) turnaround one year after establishing a major position, with shares generating a 25% total return since May 2024. Key improvements include: board refreshment with four new directors including Glenview's CEO Larry Robbins; leadership transformation under new CEO David Joyner; operational improvements exceeding earnings expectations; enhanced risk management through deleveraging; portfolio optimization; and progress toward potential share repurchases. Glenview has reduced holdings by 3.75 million shares for portfolio diversification but maintains CVS as its largest position. The firm remains confident in CVS's outlook, highlighting the company's role in serving 185 million people.

Positive

• 25% total return on investment since May 2024
• Board strengthened with four new directors and new Lead Independent Director
• Exceeded consensus earnings expectations in past two quarters
• Commitment to deleveraging and improved risk management
• Remains Glenview's largest position despite partial sale
• Increased annual guidance after Q1 results

Negative

• Suspension of material acquisitions
• Exit from certain business lines
• Glenview reduced holdings by 3.75 million shares

News Market Reaction – CVS

+0.83%

1 alert

+0.83% News Effect

On the day this news was published, CVS gained 0.83%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, May 6, 2025 /PRNewswire/ -- One year ago, we established a concentrated position in shares of CVS Health (NYSE: CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company.  Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan:

1. Board Refreshment – The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director.  The entire Board is operating cooperatively and cohesively;
   
   
2. Strengthening Culture and Leadership – CVS's leadership has undergone significant transformation under new CEO David Joyner's leadership, combining internal promotion with external recruitment while strengthening a customer-centric, accountable culture;
   
   
3. Operational Intensity – CVS exceeded consensus earnings expectations over the past two quarters and has seen operating strength and early signs of recovery across its businesses;
   
   
4. Risk Management – The Company has suspended material acquisitions, committed to deleveraging, strengthened its insurance reserve levels and established a clear path to sustainable returns on capital that will fuel future customer service and benefit stability;
   
   
5. Portfolio Enhancement and Innovation – CVS has exited or transitioned certain lines of business where economics prevent a sustainable commitment to customers while leading the industry with transparent and value-added solutions to reduce cost and complexity; and
   
   
6. Opportunistic Capital Deployment – In combination, CVS has marched closer to the time in which share repurchase can be both a responsible consideration and a creator of long-term shareholder value. 

Following healthy Q1 results and increased annual guidance, Glenview reduced its overall holdings by 3.75 million shares consistent with our fund's diversification parameters and to create buying power for further unique opportunities in this volatile macro environment. With this rebalancing, CVS Health remains our largest position, and we have no plans for additional adjustments to our CVS holdings.  Our confidence in the near, medium, and long-term outlook for CVS remains strong. 

We are grateful for the engagement and enthusiasm of the entire CVS Health team in the revitalization efforts well underway and are fully committed to making continued contributions to the vitality and long-term success of this iconic institution that strengthens the health of 185 million people.

Together we grow.

About Glenview Capital
In its 25th year of operations, Glenview Capital is a long-term investment partnership focused on fundamental investing.

Contact:
Keegan Bales
kbales@hstrategies.com

View original content:https://www.prnewswire.com/news-releases/glenview-capital-issues-statement-on-cvs-health-302447757.html

SOURCE Glenview Capital

FAQ

What changes has CVS Health (CVS) made to its board and leadership in 2024-2025?

CVS Health added four new directors including Glenview's CEO Larry Robbins, appointed a new Lead Independent Director, and underwent leadership transformation under new CEO David Joyner, combining internal promotions with external recruitment.

How has CVS stock performed since Glenview Capital's investment in May 2024?

CVS Health stock has generated a total return of 25% since Glenview Capital's investment in May 2024.

Why did Glenview Capital reduce its CVS holdings in 2025?

Glenview reduced holdings by 3.75 million shares for portfolio diversification and to create buying power for other opportunities in the volatile macro environment, while maintaining CVS as its largest position.

What operational improvements has CVS Health achieved under the new leadership?

CVS has exceeded consensus earnings expectations over the past two quarters, shown operating strength across businesses, committed to deleveraging, strengthened insurance reserve levels, and established a path to sustainable returns.

How many people does CVS Health serve as of 2025?

CVS Health serves 185 million people according to the statement.